The objective of this article is to support a logistical and operational feasibility analysis: given the research question and the environment in which we work, is it appropriate to consider an adaptive design, and are we sufficiently well prepared to deploy successfully?
EllenbergS.E., FlemingT.R., DeMetsD.L.Data Monitoring Committees in Clinical Trials: A Practical Perspective.Chichester, UK: Wiley; 2002.
8.
US Food and Drug Administration.Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees.Rockville, MD: US Food and Drug Administration; 2006.
9.
Committee for Medicinal Products for Human Use.Guideline on Data Monitoring Committees.London: EMEA; 2005.
10.
GalloP.Regulatory confidentiality issues for adaptive design trials. Drug Inf J.2006; 40: 445–450.
